SPERO THERAPEUTICS INC
Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.
Latest price
$1.06
-4.50%
Alpha Vantage · 10/30/2026
One-year price history
Adjusted daily closes · 252 observations · as of Oct 30, 2026
1 month
-15.9%
3 months
-7.8%
6 months
-57.3%
1 year
-55.1%
Year to date
-54.5%
52-week range
$1.06 – $2.98
Fundamental snapshot
Latest reported period: Jun 30, 2026
Market cap
$61.7M
P/E
8.4
P/B
1.4
P/S
1.3
Revenue
$47M
Net income
$7.38M
Diluted EPS
0.14
Gross margin
100.00%
Net margin
15.70%
Return on equity
16.20%
Total debt
$2.04M
Cash
$50.77M
Free cash flow
$19.58M
Latest eight reported quarters
Reported quarterly values, newest first
| Period | Revenue | Net income | Gross margin | Net margin | Free cash flow |
|---|---|---|---|---|---|
| Jun 30, 2026 | $0 | -$9.55M | — | — | -$5.36M |
| Mar 31, 2026 | $258K | -$7.2M | 100.00% | -2791.90% | $15.86M |
| Dec 31, 2025 | $41.3M | $31.52M | 100.00% | 76.30% | -$8.35M |
| Sep 30, 2025 | $5.44M | -$7.38M | 100.00% | -135.60% | $17.42M |
| Jun 30, 2025 | $14.19M | -$1.7M | 100.00% | -12.00% | -$17.69M |
| Mar 31, 2025 | $5.87M | -$13.87M | 100.00% | -236.10% | -$4M |
| Dec 31, 2024 | $15.04M | -$20.89M | 100.00% | -138.80% | -$23.4M |
| Sep 30, 2024 | $13.47M | -$17.15M | 100.00% | -127.30% | $12.76M |
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Recent SPRO news
All market newsNo ticker-linked stories are in the current archive.